NCT01636622 is a Phase 1 clinical trial of Vemurafenib in Advanced Cancers, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT01636622?

NCT01636622 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01636622?

Interventions in NCT01636622: Vemurafenib, Carboplatin, Paclitaxel.

What condition does NCT01636622 study?

NCT01636622 studies Advanced Cancers.

Is NCT01636622 still recruiting?

NCT01636622 is currently completed. Last updated 18 June 2020.

Last reviewed 2020-06-18 · How we verify

NCT01636622

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Vemurafenib, Carboplatin, and Paclitaxel

Completed Phase 1 Last updated 18 June 2020

What this trial tests

Phase 1 trial testing Vemurafenib in Advanced Cancers in 21 participants. Completed in 21 April 2020.

Timeline

9 July 2012

Primary endpoint
21 April 2020

21 April 2020

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	9 July 2012
Primary completion	21 April 2020
Estimated completion	21 April 2020
Sites	1 location across United States

Drugs / interventions tested

Vemurafenib (vemurafenib) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Advanced Cancers — all drugs for Advanced Cancers →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

12 and older, any sex, with Advanced Cancers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with carboplatin and paclitaxel patients with advanced cancer. The safety of the study drug combination will also be studied. Vemurafenib is designed to block a protein (called mutated BRAF) that is only found in moles (spots) of the skin and certain types of cancer cells. This drug may slow the growth of or kill these cells. Carboplatin is designed to slow the growth of cancer cells by stopping them from making new DNA (the genetic material of cells). Paclitaxel is designed to slow the growth of cancer cells by stopping them from dividing into new cells.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
Nelson BE, Roszik J, Janku F, Hong DS, et al · · 2023 · cited 15× · PMID 36801912 · DOI 10.1038/s41698-022-00341-0
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
Bhatty M, Kato S, Piha-Paul SA, Naing A, et al · · 2019 · cited 10× · PMID 30383888 · DOI 10.1002/cncr.31812
Genomics-Driven Precision Medicine in Pediatric Solid Tumors.
Suthapot P, Chiangjong W, Chaiyawat P, Choochuen P, et al · · 2023 · cited 7× · PMID 36900212 · DOI 10.3390/cancers15051418

Verify or expand the search:

Other trials of Vemurafenib

Trials testing the same drug.

NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
NCT06561360 — A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) · Phase 2 · recruiting
NCT06440850 — Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E · Phase 2 · recruiting
NCT05238831 — SMMART Adaptive Clinical Treatment (ACT) Trial · EARLY_PHASE1 · withdrawn
NCT05233332 — Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) · Phase 2 · unknown

Other recruiting trials for Advanced Cancers

Currently open trials in the same condition.

NCT06001749 — Psilocybin in Cancer Pain Study · Phase 2 · recruiting
NCT03375983 — Plasmodium Immunotherapy for Advanced Cancers · Phase 1, PHASE2 · recruiting
NCT01375114 — The Effects of Ginseng on Cancer-Related Fatigue · Phase 1, PHASE2 · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01636622 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 18 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01636622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing